New drug cocktail takes on rare skin cancer

NCT ID NCT07529405

Not yet recruiting Disease control Sponsor: Virogen Biotechnology Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase II trial tests a new drug called VG712 against an existing drug, mogamulizumab, in about 386 people with advanced mycosis fungoides, a rare type of skin lymphoma. VG712 is designed to kill cancerous immune cells by blocking protein production. The study aims to see if VG712 can delay cancer progression better than the current treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: VG712 (a fusion protein that targets and kills certain immune cells) and mogamulizumab (a targeted antibody therapy)
What this could lead to: If successful, this could offer a new treatment option for people with advanced mycosis fungoides who have not responded to other therapies.
What could go wrong: This is a Phase II trial, so it is still early. The treatment may not work better than the comparison drug, and side effects could include infusion reactions or organ damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYCOSIS FUNGOIDES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mycosis fungoides

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYCOSIS FUNGOIDES

Contacts and locations

Locations

H. Lee Moffitt Cancer Center and Research Institute

Tampa, Florida, 33612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.